癌症中Cereblon的表观遗传调节:分子机制和临床影响
Joo Mi Yi1,2
1Department of Microbiology and Immunology, College of Medicine, Inje University, Busan, 47392, South Korea. jmyi76@inje.ac.kr.
促剂甲基化在各种癌症中表观遗传地沉默Cereblon (CRBN),导致预后不佳和对免疫调节药物 (IMiDs) 的耐药性. 通过表观遗传疗法恢复CRBN表达可能会改善癌症治疗结果.
科学领域:
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 药物基因组学 药物基因组学
背景情况:
- 脑 (CRBN) 对于CRL4-CRBN E3泛素酶复合体的功能至关重要,也是癌症治疗中免疫调节药物 (IMiD) 的关键标.
- 减少CRBN表达与IMiD反应不佳和治疗耐药性相关,表明非遗传调节机制.
- 研究CRBN的表观遗传调节对于了解癌症治疗耐药性至关重要.
研究的目的:
- 分析不同癌症类型的CRBN表达模式.
- 研究促进物甲基化在调节CRBN表达中的作用.
- 评估CRBN甲基化和表达作为预后生物标志物的临床意义.
主要方法:
- 使用GENT2数据库分析CRBN表达式.
- 在癌细胞系中通过甲基化特异PCR (MSP) 和双硫酸盐测序评估CRBN甲基化状态.
- 使用TCGA和GENT2数据库与Kaplan-Meier生存分析评估的临床意义.
主要成果:
- 在乳腺癌,宫癌,头癌,肺癌和皮肤癌中,CRBN表达显著下调.
- CRBN促进剂高甲基化与乳腺癌,肺癌,急性髓性白血病和膀癌的死亡风险增加相关.
- 低CRBN表达和高促进子甲基化的结合强烈预测了乳腺癌和肺癌的不良结果.
结论:
- 在特定癌症中,CRBN表达通过促进物甲基化进行表观遗传调节,导致治疗耐药性和不良预后.
- CRBN甲基化和表达是显著的泛癌预后生物标志物.
- 表观遗传疗法具有恢复CRBN功能和克服治疗耐药性的潜力.
更多相关视频
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
相关概念视频
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
